Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18,817 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ. Signorovitch J, et al. Among authors: xie j. Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:130-7. doi: 10.1002/pds.3246. Pharmacoepidemiol Drug Saf. 2012. PMID: 22552988
Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147-2160. doi:10.1007/s12325-019-00991-w.
Song J, Gao W, Xie J, Tiwana S. Song J, et al. Among authors: xie j. Adv Ther. 2020 Feb;37(2):955-957. doi: 10.1007/s12325-019-01168-1. Epub 2019 Dec 14. Adv Ther. 2020. PMID: 31838710 Free PMC article. No abstract available.
18,817 results
You have reached the last available page of results. Please see the User Guide for more information.